A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
August 16, 2021
-
BUSINESS Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
-
BUSINESS Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
-
BUSINESS Morimoto Pharma Aims at Commercial Production of Freeze-Dried Vaccine in FY2022
August 12, 2021
-
BUSINESS Orizuru Therapeutics Boots Up to Take Over iPSC Assets from T-CiRA, Eyes IPO in 2026
August 11, 2021
-
BUSINESS HIF-PH Drugs’ Sluggish Q1 Sales Signal Tepid Uptake as Side Effect Concerns Weigh
August 10, 2021
-
BUSINESS Foreign Drug Makers Scrapping Sales Offices as Sanofi Follows GSK, Novartis, AZ
August 6, 2021
-
REGULATORY Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
-
REGULATORY Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
-
REGULATORY August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
-
REGULATORY Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
-
REGULATORY Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
-
BUSINESS Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
-
REGULATORY AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
-
ORGANIZATION New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
July 30, 2021
-
BUSINESS Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
-
ACADEMIA Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
-
REGULATORY Forxiga Clears PAFSC, in Line to Become Japan’s 1st CKD Drug in August
July 29, 2021
-
BUSINESS Keytruda Keeps Top Drug Crown in FY2020 despite Double-Digit Dip: Tally
July 28, 2021
-
BUSINESS MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…